BioNTech Results Presentation Deck

BNT311: Phase 1 / 2a - Safety profile TEAES occurring in ≥10% of patients ALT increased AST increased Anemia Asthenia Fatigue Hypothyroidism Back pain Decreased appetite Malignant neoplasm Nausea 0 17 Dose escalation cohort 10 TRAES occurring in ≥10% of patients Any TRAE TRAES in >10% of patients, by preferred term Transaminase elevation Hypothyroidism Fatigue 20 All grades, n (%) 43 (70.5) 16 (26.2) 11 (18.0) 8 (13.1) 30 All patients (N=61) Grade 3, n (%) 15 (24.6) 6 (9.8) 0 1 (1.6) T 40 50 Grade 4, n (%) 3 (4.9) 0 1 (1.6) 0 Grade 1 Grade 2 Grade 3 Grade 4+ 100 The most common treatment-related adverse events were transaminase elevations, hypothyroidism and fatigue Treatment-related transaminase elevations occurred in 26.2% of patients (9.8% of patients had grade 3 transaminase elevations) There were no patients with Grade 4 transaminase, or treatment-related bilirubin increases MTD has not been reached BIONTECH

View entire presentation